Cargando…

The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge

OBJECTIVES: More than a quarter of single-country systemic lupus erythematosus (SLE) interventional randomized clinical trials (RCTs) were conducted in China. To help develop management guidelines and set benchmarks for future SLE research, a systematic review of current trials is needed. METHODS: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Jingru, Zhou, Hang, Liu, Juan, Xiong, Feng, Yi, Ping, Cao, Pengpeng, Fang, Dorthy, Zhang, Bo, Lu, Qianjin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035534/
https://www.ncbi.nlm.nih.gov/pubmed/35479089
http://dx.doi.org/10.3389/fimmu.2022.848478
_version_ 1784693313544126464
author Tian, Jingru
Zhou, Hang
Liu, Juan
Xiong, Feng
Yi, Ping
Cao, Pengpeng
Fang, Dorthy
Zhang, Bo
Lu, Qianjin
author_facet Tian, Jingru
Zhou, Hang
Liu, Juan
Xiong, Feng
Yi, Ping
Cao, Pengpeng
Fang, Dorthy
Zhang, Bo
Lu, Qianjin
author_sort Tian, Jingru
collection PubMed
description OBJECTIVES: More than a quarter of single-country systemic lupus erythematosus (SLE) interventional randomized clinical trials (RCTs) were conducted in China. To help develop management guidelines and set benchmarks for future SLE research, a systematic review of current trials is needed. METHODS: We searched systematically three databases and four registries to summarize the interventional RCTs in mainland China and identify factors associated with participant loss. The internal validity of trials was assessed using the Cochrane risk-of-bias tool for assessing risk of bias. The odds ratio (OR) was defined as the ratio of the odds of less than 10% loss to follow-up in the presence or absence of different factors. RESULTS: A total of 188 trials met our inclusion criteria, and 15·5% of trials conducted in mainland China ranked low risk of bias. Participant loss was significantly higher among trials that had a defined primary outcome or were registered {primary outcome identification (0·02 [0·00-0·23]) and registration (0·14 [0·03-0·69])}. Trials examining traditional Chinese medicine (TCM) pharmacological treatments had an 8·16-fold (8·16 [1·28-51·98]) higher probability of having low participant loss than trials examining non-TCM pharmacological treatment trials, and trials that did not report masking status had a 15·95-fold (15·95 [2·45-103·88]) higher probability of having low participant loss than open-label trials. In addition, published articles in Chinese also had higher probability of having low participant loss (5·39 [1·10-26·37]). CONCLUSION: SLE trials conducted in mainland China were of relatively poor quality. This situation, including nonrigorous design, lack of registration, and absence of compliance reporting, needs to be ameliorated. To maintain the fundamental repeatability and comparability of mainland China SLE RCTs, transparency of the clinical trial process and complete reporting of the trial data are crucial and urgently needed.
format Online
Article
Text
id pubmed-9035534
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90355342022-04-26 The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge Tian, Jingru Zhou, Hang Liu, Juan Xiong, Feng Yi, Ping Cao, Pengpeng Fang, Dorthy Zhang, Bo Lu, Qianjin Front Immunol Immunology OBJECTIVES: More than a quarter of single-country systemic lupus erythematosus (SLE) interventional randomized clinical trials (RCTs) were conducted in China. To help develop management guidelines and set benchmarks for future SLE research, a systematic review of current trials is needed. METHODS: We searched systematically three databases and four registries to summarize the interventional RCTs in mainland China and identify factors associated with participant loss. The internal validity of trials was assessed using the Cochrane risk-of-bias tool for assessing risk of bias. The odds ratio (OR) was defined as the ratio of the odds of less than 10% loss to follow-up in the presence or absence of different factors. RESULTS: A total of 188 trials met our inclusion criteria, and 15·5% of trials conducted in mainland China ranked low risk of bias. Participant loss was significantly higher among trials that had a defined primary outcome or were registered {primary outcome identification (0·02 [0·00-0·23]) and registration (0·14 [0·03-0·69])}. Trials examining traditional Chinese medicine (TCM) pharmacological treatments had an 8·16-fold (8·16 [1·28-51·98]) higher probability of having low participant loss than trials examining non-TCM pharmacological treatment trials, and trials that did not report masking status had a 15·95-fold (15·95 [2·45-103·88]) higher probability of having low participant loss than open-label trials. In addition, published articles in Chinese also had higher probability of having low participant loss (5·39 [1·10-26·37]). CONCLUSION: SLE trials conducted in mainland China were of relatively poor quality. This situation, including nonrigorous design, lack of registration, and absence of compliance reporting, needs to be ameliorated. To maintain the fundamental repeatability and comparability of mainland China SLE RCTs, transparency of the clinical trial process and complete reporting of the trial data are crucial and urgently needed. Frontiers Media S.A. 2022-04-11 /pmc/articles/PMC9035534/ /pubmed/35479089 http://dx.doi.org/10.3389/fimmu.2022.848478 Text en Copyright © 2022 Tian, Zhou, Liu, Xiong, Yi, Cao, Fang, Zhang and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Tian, Jingru
Zhou, Hang
Liu, Juan
Xiong, Feng
Yi, Ping
Cao, Pengpeng
Fang, Dorthy
Zhang, Bo
Lu, Qianjin
The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge
title The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge
title_full The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge
title_fullStr The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge
title_full_unstemmed The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge
title_short The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge
title_sort systemic lupus erythematosus interventional trials in mainland china: a continuous challenge
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035534/
https://www.ncbi.nlm.nih.gov/pubmed/35479089
http://dx.doi.org/10.3389/fimmu.2022.848478
work_keys_str_mv AT tianjingru thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT zhouhang thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT liujuan thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT xiongfeng thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT yiping thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT caopengpeng thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT fangdorthy thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT zhangbo thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT luqianjin thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT tianjingru systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT zhouhang systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT liujuan systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT xiongfeng systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT yiping systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT caopengpeng systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT fangdorthy systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT zhangbo systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge
AT luqianjin systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge